Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development expense	$ 23,704	$ 20,180
General and administrative	7,758	4,945
Total operating expenses	31,462	25,125
Loss from operations	(31,462)	(25,125)
Other income (expense), net:
Interest income	4,519	2,367
Other expense	(1)	0
Total other income (expense), net	4,518	2,367
Loss before income taxes	(26,944)	(22,758)
Income tax expense	(5)	(23)
Net loss and comprehensive loss	(26,949)	(22,781)
Net loss attributable to common stockholders-basic	(26,949)	(22,781)
Net loss attributable to common stockholders-diluted	$ (26,949)	$ (22,781)
Weighted-average common shares outstanding-basic	24,809,869	18,954,914
Weighted-average common shares outstanding-diluted	24,809,869	18,954,914
Net loss per share attributable to common stockholders-basic	$ (1.09)	$ (1.2)
Net loss per share attributable to common stockholders-diluted	$ (1.09)	$ (1.2)